Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Taselisib is a potent and selective phosphatidylinositide 3-kinase (PI3K) inhibitor. The present article reports the first study of taselisib administration in Japanese patients. The aim of this 2-stage, phase I, multicenter, open-label, dose-escalation study was to evaluate the safety, pharmacokinetics, and preliminary efficacy of taselisib as monotherapy in Japanese patients with advanced solid tumors (stage 1), and as part of combination therapy in Japanese patients with hormone receptor (HR)-positive locally advanced or recurrent breast cancer (stage 2). In stage 1, oral taselisib tablets 2, 4, and 6 mg/d were given in 28-day cycles. In stage 2, successive cohorts of patients received oral taselisib tablets (2 or 4 mg/d) with i.m. fulvestrant 500 mg. Nine and 6 patients were enrolled in stage 1 and stage 2, respectively. Taselisib was well tolerated. No dose-limiting toxicities were experienced in any cohort of patients and no deaths were observed. The most common treatment-related adverse events in stage 1 and stage 2, respectively, were rash (55.6%, 66.7%), diarrhea (44.4%, 66.7%), and stomatitis (44.4%, 66.7%). Taselisib was rapidly absorbed after dosage; its half-life was 12.9-32.0 hours in stage 1 and 16.1-26.5 hours in stage 2. Two patients achieved partial response (PR), 5 patients had stable disease (SD) and 2 patients had progressive disease (PD) in stage 1, and 1 patient had PR and 3 patients had SD in stage 2. All patients with PR were positive for PIK3CA gene mutations. These preliminary data suggest that taselisib may be effective in patients with PIK3CA-mutated solid tumors or HR-positive advanced breast cancer.
['Tamura|Kenji|K|http://orcid.org/0000-0002-3514-9927', 'Kodaira|Makoto|M|', 'Shimizu|Chikako|C|', 'Yonemori|Kan|K|', 'Yunokawa|Mayu|M|', 'Shimomura|Akihiko|A|', 'Kobayashi|Takayuki|T|', 'Nakano|Kenji|K|', 'Tomomatsu|Junichi|J|', 'Ito|Yoshinori|Y|', 'Tanaka|Jun|J|', 'Kuriki|Hiroshi|H|', 'Gu|Zhaodi|Z|', 'Takahashi|Shunji|S|']
D000368:Aged D001943:Breast Neoplasms D005260:Female D006801:Humans D007093:Imidazoles D008297:Male D008875:Middle Aged D009154:Mutation D009369:Neoplasms D010077:Oxazepines D019869:Phosphatidylinositol 3-Kinases D000081082:Phosphoinositide-3 Kinase Inhibitors D011960:Receptors, Estrogen
taselisib Japanese breast cancer PI 3-kinase protein kinase inhibitor